FTX-6058 is a potent and orally active inhibitor of Embryonic Ectoderm Development (EED). FTX-6058 can induce HbF protein expression in cell and murine models. FTX-6058 can be used for the research of select hemoglobinopathies, including sickle cell disease and β-thalassemia[1][2].
FTX-6058 inhibits PRC2 via binding to EED, which induces robust HbF protein expression in both cell and murine models[2].
[1]. Boerner LK. Virtual meeting delivers first time drug structures. April 12, 2021.
[2]. Fulcrum Therapeutics Presents Published Structure of Investigational Small Molecule FTX-6058 at the American Chemical Society (ACS) Spring 2021 Virtual Conference.